Month: August 2020

The sales of AB Vilkyskiu pienine Group July 2020

Written by Customer Service on August 10, 2020. Posted in Public Companies.

The consolidated sales for July 2020 amounted to 10.6 million EUR – 12.7 % increase comparing to July 2019. The sales of the Group for period January – July 2020 amounted to 66.4 million EUR – 5.3% increase comparing to the same period last year.Vilija MilaseviciuteEconomics and finance directorPhone: +370 441 55 102

AB Vilkyškių pieninė grupės pardavimai 2020 m. liepos mėnesį

Written by Customer Service on August 10, 2020. Posted in Public Companies.

2020 m. liepos mėnesį konsoliduotos pardavimų pajamos buvo 10.6 mln. Eur arba 12.7 % didesnės negu 2019 liepos mėnesį. Grupės pardavimai 2020 m. sausio – liepos mėn. buvo 66.4 mln. EUR arba 5.3 % didesni negu per tą patį laikotarpį 2019 m.Vilija MilaševičiutėEkonomikos ir finansų direktorėTel.: +370 441 55 102

Børsmeddelelse nr. 18.2020 Opdaterede vedtægter

Written by Customer Service on August 10, 2020. Posted in Public Companies.

På selskabets ekstraordinære generalforsamling d. 20. maj 2020 vedtog generalforsamlingen to ændringer af selskabets vedtægter. De ændrede vedtægter er nu registreret hos Erhvervsstyrelsen. Selskabets opdaterede vedtægter fremsendes til orientering vedhæftet.Ændringerne og baggrunden herfor er nærmere beskrevet i selskabets børsmeddelelser nr. 06.2020 af d. 25. marts 2020 og nr. 10.2020 af d. 28. april 2020.Med venlig hilsenSmallCap Danmark A/SSteffen SchouwDirektørVedhæftede filerAS_18_2020_OpdateredeVedtægter_100820Vedtægter SmallCap DK AS 200520

ALSTOM SA: Statement following Bombardier Inc H1 publication

Written by Customer Service on August 10, 2020. Posted in Public Companies.

Statement following Bombardier Inc H1 publication10 August 2020 – Alstom has reviewed the information communicated to the market by Bombardier Inc on August 6, 2020, particularly with regards to the financial and operational performance of Bombardier Transportation.Alstom remains convinced of the strong strategic rationale for the acquisition of Bombardier Transportation and is confident in its ability to restore in the medium term the profitability and commercial performance of the business.However, the quarterly announcement points to unexpected and negative developments regarding Bombardier Transportation, which is currently facing challenges, especially when compared to the information available prior to the February 17, 2020 announcement regarding Alstom’s intended acquisition of Bombardier Transportation.Alstom will take into account...

ALSTOM SA : Communication à la suite de la publication des résultats du premier semestre 2020 de Bombardier Inc

Written by Customer Service on August 10, 2020. Posted in Public Companies.

Communication à la suite de la publication des résultats du premier semestre 2020 de Bombardier Inc10 août 2020 – Alstom a revu les informations communiquées au marché par Bombardier Inc le 6 août 2020, en particulier s’agissant de la performance financière et opérationnelle de Bombardier Transport.Alstom maintient sa forte conviction dans le rationnel stratégique de l’acquisition de Bombardier Transport et est confiante dans sa capacité à rétablir à moyen terme la rentabilité et les performances commerciales des activités de Bombardier Transport.Néanmoins, l’annonce des résultats trimestriels souligne des évolutions négatives et non prévues quant à Bombardier Transport, laquelle fait face actuellement à des difficultés, notamment par rapport aux informations disponibles en amont de l’annonce, le 17 février 2020, de l’acquisition envisagée...

Chi-Med Plans to Submit Marketing Authorization Application for Surufatinib Following Scientific Advice from EMA’s CHMP

Written by Customer Service on August 10, 2020. Posted in Public Companies.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that it received scientific advice from the European Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”) for surufatinib for the treatment of patients with advanced neuroendocrine tumors (“NET”). Based on the CHMP advice, we have concluded that the completed SANET-ep (non-pancreatic NET) and SANET-p (pancreatic NET) studies, along with existing data from surufatinib in U.S. non-pancreatic and pancreatic NET patients, could form the basis to support a marketing authorization application (“MAA”). Given that no filing issues were identified, the MAA submission is planned for 2021, following submission for the U.S. Food and Drug Administration...

New study published in the Journal of the National Cancer Institute concludes that Epi proColon® is the test of choice for the millions of individuals not willing to participate in FIT or colonoscopy screening

Written by Customer Service on August 10, 2020. Posted in Public Companies.

Under the primary base case analysis, annual mSEPT9 screening resulted in more Quality-adjusted-life-years gained (QALYG), CRC cases averted and CRC deaths averted than both annual FIT screening and Cologuard® every three years, albeit at a higher colonoscopy referral rateAnnual Epi proColon was found to be more cost-effective than Cologuard under all five modeling scenarios analyzedBERLIN and SAN DIEGO, Aug. 10, 2020 (GLOBE NEWSWIRE) — Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) announces that a study published by the NCI-sponsored cancer intervention and surveillance modeling network (CISNET) in the Journal of the National Cancer Institute reported that by comparing the incremental cost-effectiveness of CTC, PillCam, mtSDNA (Cologuard) and mSEPT9 (Epi proColon), the study revealed that...

Oma Säästöpankki Oyj:n puolivuosikatsaus 1.1.-30.6.2020: Liiketoiminnan vahva kehitys jatkui vaativassa toimintaympäristössä

Written by Customer Service on August 10, 2020. Posted in Earnings Releases And Operating Results.

OMA SÄÄSTÖPANKKI OYJ, PÖRSSITIEDOTE 10.8.2020 KLO 8.55, PUOLIVUOSIKATSAUS 1.1.-30.6.2020 Oma Säästöpankki Oyj:n puolivuosikatsaus 1.1.-30.6.2020: Liiketoiminnan vahva kehitys jatkui vaativassa toimintaympäristössäTämä tiedote on tiivistelmä Oma Säästöpankki Oyj:n (OmaSp) tammi-kesäkuun 2020 puolivuosikatsauksesta, joka on luettavissa kokonaisuudessaan tämän pörssitiedotteen liitteenä olevasta pdf-tiedostosta. Lisäksi yhtiö julkaisee puolivuosikatsauksen yhteydessä Pilari III mukaiset tiedot vakavaraisuudesta ja riskienhallinnasta erillisenä raporttina, joka on saatavilla tiedotteen liitteenä pdf-tiedostona. Molemmat raportit ovat saatavilla myös yhtiön verkkosivuilla osoitteessa www.omasp.fi. Toimitusjohtaja Pasi Sydänlammi:”Voimme olla tyytyväisiä liiketoiminnan kehitykseen alkuvuoden aikana. Korkokatteemme kasvoi lähes 14 % ja liiketoiminnan...

Oma Savings Bank Plc’s Half-Year Financial Report 1.1.-30.6.2020: Business development continued to be strong in a demanding operating environment

Written by Customer Service on August 10, 2020. Posted in Earnings Releases And Operating Results.

OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE 10 AUGUST 2020 AT 8.55 A.M. EET, HALF-YEAR FINANCIAL REPORTOma Savings Bank Plc’s Half-Year Financial Report 1.1.-30.6.2020: Business development continued to be strong in a demanding operating environmentThis release is a summary of Oma Savings Bank’s (OmaS) January-June 2020 Half-Year Financial Report, which can be read from the pdf file attached to this stock exchange release. In addition, alongside with the Half-Year Financial Report, the Company also publishes Disclosure information on capital adequacy and risk management in accordance with the Pillar III as a separate report, available as an attached pdf file. Both reports are also available on the Company’s website at www.omasp.fi.CEO Pasi Sydänlammi:”We can be pleased with the development of the business in the early part...

FDA approves Roche’s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older

Written by Customer Service on August 10, 2020. Posted in Public Companies.

In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMAEvrysdi helped infants survive without permanent ventilation and achieve the ability to sit without support, a key motor milestone not normally seen in the natural course of the diseaseEvrysdi is the first and only medicine for SMA that can be taken at home Basel, 10 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Evrysdi™ (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months of age and older. Evrysdi showed clinically-meaningful improvements in motor function across two clinical trials in people with varying ages and levels...

Month: August 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals